Stevens-Johnson syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence of SJS is approximately 2-7 per 1000,000 individuals per year.<ref name="pmid2036028">{{cite journal| author=Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M et al.| title=A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. | journal=Arch Dermatol | year= 1991 | volume= 127 | issue= 6 | pages= 831-8 | pmid=2036028 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2036028  }}</ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The incidences of SJS, SJS-TEN, and TEN were found to be a mean 5.3, 0.8, and 0.4 cases per million children per year in the US<ref name="pmid28285784">{{cite journal| author=Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI| title=Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. | journal=J Am Acad Dermatol | year= 2017 | volume= 76 | issue= 5 | pages= 811-817.e4 | pmid=28285784 | doi=10.1016/j.jaad.2016.12.024 | pmc=5502094 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28285784  }}</ref>
 
*The mean estimated incidences of SJS, SJS/TEN, and TEN were found to be 9.2, 1.6, and 1.9 per million adults per year in the US<ref name="pmid27039263">{{cite journal| author=Hsu DY, Brieva J, Silverberg NB, Silverberg JI| title=Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. | journal=J Invest Dermatol | year= 2016 | volume= 136 | issue= 7 | pages= 1387-1397 | pmid=27039263 | doi=10.1016/j.jid.2016.03.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27039263  }}</ref>
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*Between years 2009-2012, the Mean adjusted mortality was 4.8% for SJS, 19.4% for SJS/TEN, and 14.8% for TEN<ref name="pmid270392632">{{cite journal| author=Hsu DY, Brieva J, Silverberg NB, Silverberg JI| title=Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. | journal=J Invest Dermatol | year= 2016 | volume= 136 | issue= 7 | pages= 1387-1397 | pmid=27039263 | doi=10.1016/j.jid.2016.03.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27039263  }}</ref>
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may develop SJS.
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*The incidence of SJS might be higher in Non White/Multiracial people as compared to White{{cite web |url=https://doi.org/10.1016/j.jid.2016.03.023 |title=Redirecting |format= |work= |accessdate=}}
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Women are more commonly affected by SJS than males{{cite web |url=https://doi.org/10.1016/j.jid.2016.03.023 |title=Redirecting |format= |work= |accessdate=}}.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==

Revision as of 21:34, 29 August 2018

Stevens-Johnson syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stevens-Johnson Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stevens-Johnson syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stevens-Johnson syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stevens-Johnson syndrome epidemiology and demographics

CDC on Stevens-Johnson syndrome epidemiology and demographics

Stevens-Johnson syndrome epidemiology and demographics in the news

Blogs on Stevens-Johnson syndrome epidemiology and demographics

Directions to Hospitals Treating Stevens-Johnson syndrome

Risk calculators and risk factors for Stevens-Johnson syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of SJS is approximately 2-7 per 1000,000 individuals per year.[1]
  • The incidences of SJS, SJS-TEN, and TEN were found to be a mean 5.3, 0.8, and 0.4 cases per million children per year in the US[2]
  • The mean estimated incidences of SJS, SJS/TEN, and TEN were found to be 9.2, 1.6, and 1.9 per million adults per year in the US[3]

Case-fatality rate/Mortality rate

  • Between years 2009-2012, the Mean adjusted mortality was 4.8% for SJS, 19.4% for SJS/TEN, and 14.8% for TEN[4]

Age

  • Patients of all age groups may develop SJS.

Race

  • The incidence of SJS might be higher in Non White/Multiracial people as compared to White"Redirecting".

Gender

  • Women are more commonly affected by SJS than males"Redirecting"..

References

  1. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M; et al. (1991). "A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures". Arch Dermatol. 127 (6): 831–8. PMID 2036028.
  2. Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI (2017). "Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States". J Am Acad Dermatol. 76 (5): 811–817.e4. doi:10.1016/j.jaad.2016.12.024. PMC 5502094. PMID 28285784.
  3. Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). "Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults". J Invest Dermatol. 136 (7): 1387–1397. doi:10.1016/j.jid.2016.03.023. PMID 27039263.
  4. Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). "Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults". J Invest Dermatol. 136 (7): 1387–1397. doi:10.1016/j.jid.2016.03.023. PMID 27039263.

Template:WH Template:WS